These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24898669)

  • 1. New anti-CD20 monoclonal antibodies: which is the best?
    Gagez AL; Cartron G
    Leuk Lymphoma; 2015 Jan; 56(1):1-2. PubMed ID: 24898669
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
    Ganjoo KN; de Vos S; Pohlman BL; Flinn IW; Forero-Torres A; Enas NH; Cronier DM; Dang NH; Foon KA; Carpenter SP; Slapak CA; Link BK; Smith MR; Mapara MY; Wooldridge JE
    Leuk Lymphoma; 2015 Jan; 56(1):42-8. PubMed ID: 24717109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
    Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
    Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line obinutuzumab for follicular lymphoma.
    Baker H
    Lancet Oncol; 2017 Nov; 18(11):e648. PubMed ID: 29033196
    [No Abstract]   [Full Text] [Related]  

  • 5. Case of paraneoplastic pemphigus with follicular lymphoma treated with rituximab.
    Aoi J; Makino K; Sakai K; Masuguchi S; Fukushima S; Jinnin M; Inoue Y; Koga H; Hashimoto T; Ihn H
    J Dermatol; 2013 Apr; 40(4):285-6. PubMed ID: 23398274
    [No Abstract]   [Full Text] [Related]  

  • 6. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment approaches to asymptomatic follicular lymphoma.
    Sarkozy C; Salles G
    Expert Rev Hematol; 2013 Dec; 6(6):747-58. PubMed ID: 24219551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.
    Tobinai K; Ogura M; Kobayashi Y; Uchida T; Watanabe T; Oyama T; Maruyama D; Suzuki T; Mori M; Kasai M; Cronier D; Wooldridge JE; Koshiji M
    Cancer Sci; 2011 Feb; 102(2):432-8. PubMed ID: 21205069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Composite lymphoma of the orbit treated with rituximab.
    Kang SJ; Schmack I; Wojno TH; Grossniklaus HE
    Ophthalmic Plast Reconstr Surg; 2007; 23(2):143-4. PubMed ID: 17413631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
    Trnený M
    Vnitr Lek; 2007 Oct; 53(10):1029-30. PubMed ID: 18072423
    [No Abstract]   [Full Text] [Related]  

  • 12. [Novel monoclonal antibodies for the treatment of malignant lymphomas].
    Maruyama D
    Rinsho Ketsueki; 2011 Aug; 52(8):618-26. PubMed ID: 21897067
    [No Abstract]   [Full Text] [Related]  

  • 13. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
    Barker CA; Yahalom J
    J Clin Oncol; 2010 Aug; 28(24):e426; author reply e427-8. PubMed ID: 20566995
    [No Abstract]   [Full Text] [Related]  

  • 15. FCGR3A polymorphism story: a new piece of the puzzle.
    Cartron G
    Leuk Lymphoma; 2009 Sep; 50(9):1401-2. PubMed ID: 19672769
    [No Abstract]   [Full Text] [Related]  

  • 16. Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line.
    Smith MR; Jin F; Joshi I
    Br J Haematol; 2014 Apr; 165(1):151-3. PubMed ID: 24386925
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in the management of follicular lymphoma.
    Seiler TM; Hiddemann W
    Curr Opin Oncol; 2012 Nov; 24(6):742-7. PubMed ID: 22960557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
    Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
    Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
    [No Abstract]   [Full Text] [Related]  

  • 19. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma.
    Lejeune M; Alvaro T
    Haematologica; 2009 Jan; 94(1):16-21. PubMed ID: 19118376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.